Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies
An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies
Investigator
Trial Phase
Phase II
Study Number
NCT02952508
Local Study ID
9847
Trial Contact Phone
800-804-8824 / 206-606-1024
Summary
This study evaluates CLR 131 in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL) who have been previously treated with standard therapy for their underlying malignancy.
Trial Eligibility
*For Eligibility information, look up the trial at NIH by clicking on the Study Number above.*
Other eligibility criteria may apply.
Trial Exclusions
Other exclusion criteria may apply.
Trial Keywords
Leukemia, Chronic Lymphocytic (CLL); Hematologic Malignancies; Leukemia; Lymphoma; Lymphoproliferative Disorders; Multiple Myeloma (MM); Lymphoma, Non-Hodgkin (NHL); Leukemia, Lymphoid; Immunoproliferative Disorders; Waldenstrom Macroglobulinemia; Lymphoma, Mantle-Cell; Cardiovascular Diseases; Lymphoma, B-Cell; Leukemia, B-Cell; Lymphoma, Small Lymphocytic (SLL); Leukemia, Lymphocytic, Chronic, B-Cell; Paraproteinemias; Lymphoma, Large B-Cell, Diffuse; Immune System Diseases; Hemostatic Disorders; Lymphoma, Marginal Zone
See this trial at ClinicalTrials.gov

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.